Loading...
XKRX005690
Market cap331mUSD
Dec 27, Last price  
8,280.00KRW
1D
-0.98%
1Q
47.19%
Jan 2017
56.26%
Name

Pharmicell Co Ltd

Chart & Performance

D1W1MN
XKRX:005690 chart
P/E
138.86
P/S
8.84
EPS
59.63
Div Yield, %
0.00%
Shrs. gr., 5y
0.25%
Rev. gr., 5y
14.68%
Revenues
56.23b
-6.57%
12,262,427,0008,327,605,0007,188,425,0006,368,840,00010,282,423,52011,111,800,24033,405,394,27020,155,408,36025,176,279,99027,839,155,88025,197,458,94028,351,801,13032,481,967,12037,752,047,60050,893,545,76060,181,806,97056,227,378,925
Net income
3.58b
-56.69%
-907,860,000-4,432,368,000-3,953,213,000-13,832,579,000-18,172,653,000-17,642,754,530-25,700,634,600-28,768,437,020-6,390,211,570-676,712,100-39,196,611,390-12,680,884,1704,347,128,2805,241,801,2509,450,907,1608,261,768,8203,577,983,630
CFO
11.81b
+49.28%
-745,665,0002,383,405,000-5,141,365,000-5,550,394,000-16,166,405,990-11,868,349,760-2,687,726,820-8,772,026,860-2,411,175,620988,968,270-2,007,324,1003,404,989,340-75,498,8808,978,054,530-5,222,199,6407,914,448,21011,814,411,690
Earnings
Feb 11, 2025

Profile

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.
URL
http://www.pharmicell.com/
IPO date
May 20, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
56,227,379
-6.57%
60,181,807
18.25%
50,893,546
34.81%
Cost of revenue
51,099,670
45,659,952
36,494,806
Unusual Expense (Income)
NOPBT
5,127,709
14,521,855
14,398,740
NOPBT Margin
9.12%
24.13%
28.29%
Operating Taxes
1,154,074
(4,915,804)
377,717
Tax Rate
22.51%
2.62%
NOPAT
3,973,635
19,437,659
14,021,022
Net income
3,577,984
-56.69%
8,261,769
-12.58%
9,450,907
80.30%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
2,637,517
16,794,663
17,163,404
Long-term debt
975,980
213,135
284,493
Deferred revenue
279,224
371,929
466,226
Other long-term liabilities
3,689,206
(5,960,997)
110
Net debt
(10,457,531)
2,647,018
(8,765,525)
Cash flow
Cash from operating activities
11,814,412
7,914,448
(5,222,200)
CAPEX
(6,021,517)
(18,957,716)
(4,320,244)
Cash from investing activities
5,915,783
(20,532,117)
(9,345,099)
Cash from financing activities
(18,713,126)
(269,807)
18,512,491
FCF
726,208
(75,491)
2,504,921
Balance
Cash
14,025,369
25,959,881
36,243,783
Long term investments
45,659
(11,599,101)
(10,030,361)
Excess cash
11,259,659
11,351,690
23,668,745
Stockholders' equity
31,099,539
(108,006,164)
(121,556,771)
Invested Capital
69,460,921
198,973,152
204,624,307
ROIC
2.96%
9.63%
7.10%
ROCE
5.87%
14.39%
16.36%
EV
Common stock shares outstanding
60,004
59,958
59,946
Price
6,070.00
-46.28%
11,300.00
-13.41%
13,050.00
-24.57%
Market cap
364,224,365
-46.24%
677,526,304
-13.39%
782,295,300
-24.57%
EV
353,766,834
680,173,322
773,529,775
EBITDA
7,969,117
16,707,116
16,134,584
EV/EBITDA
44.39
40.71
47.94
Interest
866,883
746,199
1,682,921
Interest/NOPBT
16.91%
5.14%
11.69%